Syngene International Limited has announced a comprehensive leadership restructuring that will see significant changes in its top management positions starting in 2026. The Board of Directors, following recommendations from the Nomination and Remuneration Committee, has approved multiple key appointments and role transitions that will shape the company's future direction.

Leadership Transition Details

The most notable change involves Ms. Kiran Mazumdar Shaw's elevation from Non-Executive Chairperson to Executive Chairperson, marking her transition to a Key Managerial Personnel role. This appointment will be effective from April 01, 2026, for a period of five years, subject to shareholder approval.

Executive Appointments and Departures

Mr. Peter Bains will step down from his position as Managing Director & Chief Executive Officer, with his resignation taking effect from the close of business hours on June 30, 2026. His departure will be followed by the appointment of Mr. Siddharth Mittal as Additional Director, designated as Managing Director & Chief Executive Officer.

Mr. Mittal's appointment includes designation as a Key Managerial Personnel and membership in the Executive Committee. His five-year term will commence on July 01, 2026, subject to shareholder approval. The company has confirmed that Mr. Mittal is not debarred from holding directorial positions by SEBI or any other regulatory authority.

Leadership Profiles and Experience

Ms. Kiran Mazumdar Shaw brings over four decades of biotechnology experience as the founder of Biocon Group, having led the organization since its inception in 1978. Under her leadership, Biocon has evolved into a global biopharmaceutical enterprise focused on innovation and affordable healthcare. She has received several national and international honors, including the Padma Shri and Padma Bhushan.

Mr. Siddharth Mittal joins from his role as Managing Director and CEO of Biocon Limited, bringing over two decades of experience in strategic finance, mergers and acquisitions, and general management. He initially joined Biocon in May 2013, serving as President & Chief Financial Officer until November 2019.

Strategic Impact and Business Focus

During his tenure at Biocon, Mr. Mittal contributed significantly to the growth of the biosimilars business and its transition into Biocon Biologics in 2019. Under his leadership, Biocon expanded into complex peptides and GLP-1 therapies, entering strategically significant segments in modern pharmaceuticals.

He also spearheaded the company's entry into the Generic Formulations segment, building a portfolio of over 20 products across global markets. These leadership changes represent a strategic transition for Syngene International as it continues to strengthen its position in the biotechnology services sector.

Syngene International Limited has announced a scheduled virtual meeting with institutional investor OrbiMed Advisors LLC, demonstrating the company's continued engagement with key stakeholders in the investment community.

Meeting Details and Regulatory Compliance

The pharmaceutical services company has formally notified both BSE Limited and the National Stock Exchange of India about the upcoming investor interaction, fulfilling its obligations under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Information Disclosure Guidelines

Syngene International has explicitly stated that no Unpublished Price Sensitive Information (UPSI) will be disclosed during the scheduled analyst and investor meeting. This commitment ensures compliance with regulatory frameworks governing information sharing between listed companies and institutional investors.

Corporate Communication Protocol

The notification, dated March 16, 2026, was signed by Chethan Yogesh, Company Secretary and Compliance Officer, and submitted to both major Indian stock exchanges. The company has also confirmed that details of this meeting will be made available on its official website at www.syngeneintl.com , ensuring transparency in corporate communications.

About the Engagement

The virtual meeting format reflects modern corporate practices for investor relations, allowing efficient communication between the Bengaluru-based pharmaceutical services company and international institutional investors. OrbiMed Advisors LLC represents a significant institutional investor in the healthcare and life sciences sector, making this engagement particularly relevant for Syngene International's stakeholder relations.